Antineoplastics
1
Reactions 1472, p7 - 5 Oct 2013 S Antineoplastics Various toxicities: 7 case reports Seven patients with hepatitis C developed various toxicities while receiving chemotherapy for invasive ductal breast carcinoma [routes, dosages, durations of treatment to reactions onset and outcomes not stated]. A 63-year-old woman with stage IIA breast cancer developed grade 4 neutropenia, febrile neutropenia and grade 3 thrombocytopenia while receiving epirubicin and cyclophosphamide. A 50-year-old woman with stage IIIa hormone receptor (HR)-positive breast cancer developed grade 4 neutropenia and grade 1 thrombocytopenia while receiving epirubicin and cyclophosphamide. She subsequently developed grade 4 neutropenia and febrile neutropenia during treatment with docetaxel. The dosage of docetaxel was reduced by 75%. A 61-year-old woman with stage IIB human epidermal growth factor-2 (HER2)-positive breast cancer developed grade 4 neutropenia and grade 1 thrombocytopenia while receiving docetaxel, cyclophosphamide and trastuzumab. A 67-year-old woman with liver cirrhosis and stage IV breast cancer developed grade 4 neutropenia, febrile neutropenia, grade 3 thrombocytopenia and grade 1 elevated transaminases during treatment with epirubicin and cyclophosphamide. The dosages of epirubicin and cyclophosphamide were reduced by 75%. A 69-year-old woman with stage IIA HER2-positive breast cancer developed grade 3 neutropenia while receiving docetaxel, cyclophosphamide and trastuzumab. A 60-year-old woman with stage IIA breast cancer developed grade 4 neutropenia, febrile neutropenia and grade 3 thrombocytopenia during treatment with epirubicin and cyclophosphamide. She subsequently developed grade 4 neutropenia and grade 2 thrombocytopenia while receiving weekly paclitaxel. A 74-year-old woman with liver cirrhosis and stage IV HR- positive breast cancer developed grade 4 neutropenia and grade 3 thrombocytopenia while receiving gemcitabine. The dosage of gemcitabine was reduced by 75%. Author comment: "Caution regarding neutropenia/ febrile neutropenia is warranted." Miura Y, et al. The safety of chemotherapy for breast cancer patients with hepatitis c virus infection. Journal of Cancer 4: 519-523, No. 6, Jan 2013. Available from: URL: http://dx.doi.org/10.7150/jca.6231 - Japan 803093517 1 Reactions 5 Oct 2013 No. 1472 0114-9954/13/1472-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1472, p7 - 5 Oct 2013
SAntineoplastics
Various toxicities: 7 case reportsSeven patients with hepatitis C developed various toxicities
while receiving chemotherapy for invasive ductal breastcarcinoma [routes, dosages, durations of treatment to reactionsonset and outcomes not stated].
A 63-year-old woman with stage IIA breast cancerdeveloped grade 4 neutropenia, febrile neutropenia andgrade 3 thrombocytopenia while receiving epirubicin andcyclophosphamide.
A 50-year-old woman with stage IIIa hormone receptor(HR)-positive breast cancer developed grade 4 neutropeniaand grade 1 thrombocytopenia while receiving epirubicin andcyclophosphamide. She subsequently developed grade 4neutropenia and febrile neutropenia during treatment withdocetaxel. The dosage of docetaxel was reduced by 75%.
A 61-year-old woman with stage IIB human epidermalgrowth factor-2 (HER2)-positive breast cancer developedgrade 4 neutropenia and grade 1 thrombocytopenia whilereceiving docetaxel, cyclophosphamide and trastuzumab.
A 67-year-old woman with liver cirrhosis and stage IV breastcancer developed grade 4 neutropenia, febrile neutropenia,grade 3 thrombocytopenia and grade 1 elevated transaminasesduring treatment with epirubicin and cyclophosphamide. Thedosages of epirubicin and cyclophosphamide were reduced by75%.
A 69-year-old woman with stage IIA HER2-positive breastcancer developed grade 3 neutropenia while receivingdocetaxel, cyclophosphamide and trastuzumab.
A 60-year-old woman with stage IIA breast cancerdeveloped grade 4 neutropenia, febrile neutropenia andgrade 3 thrombocytopenia during treatment with epirubicinand cyclophosphamide. She subsequently developed grade 4neutropenia and grade 2 thrombocytopenia while receivingweekly paclitaxel.
A 74-year-old woman with liver cirrhosis and stage IV HR-positive breast cancer developed grade 4 neutropenia andgrade 3 thrombocytopenia while receiving gemcitabine. Thedosage of gemcitabine was reduced by 75%.
Author comment: "Caution regarding neutropenia/ febrileneutropenia is warranted."Miura Y, et al. The safety of chemotherapy for breast cancer patients with hepatitisc virus infection. Journal of Cancer 4: 519-523, No. 6, Jan 2013. Available from:URL: http://dx.doi.org/10.7150/jca.6231 - Japan 803093517
1
Reactions 5 Oct 2013 No. 14720114-9954/13/1472-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
